title: Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy.
abstract: To evaluate the effects of achieved systolic blood pressure (SBP) during treatment on cardiovascular (CV) outcomes, the authors measured event rates of a composite primary endpoint (CV death or nonfatal myocardial infarction or stroke) at on-treatment SBPs of ≥140 mm Hg and the 10 mm Hg intervals of <140 mm Hg, <130 mm Hg, and <120 mm Hg in 6459 patients with diabetes (mean age, 67) and 4246 patients without diabetes (mean age, 69) from the Avoiding Cardiovascular Events in Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. In the diabetic cohort, the primary endpoint was 49% lower (P<.001) at <140 mm Hg than at ≥140 mm Hg, and the separate components of this endpoint were also significantly reduced. Further SBP reductions did not improve outcomes, and at <120 mm Hg they were no longer different (except for stroke) from ≥140 mm Hg. In contrast, in the nondiabetic cohort, the primary endpoint event rate fell steadily (although not significantly) through the decreasing SBP categories until it was reduced by 45% (P=.0413) at <120 mm Hg. Total stroke rates for both the diabetic (-56%, P=.0120) and nondiabetic (-68%, P=.0067) cohorts were lowest at <120 mm Hg, and adverse renal events (serum creatinine increase ≥50%) were significantly lowest in the range of 130 mm Hg to 139 mm Hg for both cohorts. Diabetic patients (<140 mm Hg or <130 mm Hg) and nondiabetic patients (<120 mm Hg) may require different SBP targets for optimal CV protection, although stroke and renal considerations should also influence the selection of blood pressure targets.
authors.affiliation: SUNY Downstate College of Medicine, Brooklyn, NY.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Weber
authors.affiliation: University of Nevada, Reno, NV.|School of Medicine, Renown Institute for Heart and Vascular Health, Reno, NV.
authors.forename: Michael
authors.initials: M
authors.lastname: Bloch
authors.affiliation: The University of Chicago Medicine, Chicago, IL.
authors.forename: George L
authors.initials: GL
authors.lastname: Bakris
authors.affiliation: University of Maryland, Baltimore, MD.
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Weir
authors.affiliation: Novartis Pharmaceuticals, East Hanover, NJ.
authors.forename: Dion H
authors.initials: DH
authors.lastname: Zappe
authors.affiliation: Sahlgrenska University Hospital, Goteborg, Sweden.
authors.forename: Bjorn
authors.initials: B
authors.lastname: Dahlof
authors.affiliation: Duke University School of Medicine, Durham, NC.
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Velazquez
authors.affiliation: University of Michigan, Ann Arbor, MI.
authors.forename: Bertram
authors.initials: B
authors.lastname: Pitt
authors.affiliation: Medical University of South Carolina, Charleston, SC.
authors.forename: Jan N
authors.initials: JN
authors.lastname: Basile
authors.affiliation: University of Michigan, Ann Arbor, MI.
authors.forename: Kenneth
authors.initials: K
authors.lastname: Jamerson
authors.affiliation: Novartis Pharmaceuticals, East Hanover, NJ.
authors.forename: Tsushung A
authors.initials: TA
authors.lastname: Hua
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D001795:Blood Pressure Determination; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000503:physiopathology; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D015994:Incidence; D008297:Male; D009203:Myocardial Infarction / Q000453:epidemiology / Q000209:etiology*; D011446:Prospective Studies; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D020521:Stroke / Q000453:epidemiology / Q000209:etiology*; D015996:Survival Rate / Q000639:trends; D013599:Systole; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
chemical_list: D000959:Antihypertensive Agents